Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"
Deborah M. Eng, MS, MA and Scott J. Schweikart, JD, MBE
A just culture perspective suggests that punitive responses to those who err should be reserved for those who have willfully and irremediably caused harm.
AMA J Ethics. 2020;22(9):E779-783. doi:
10.1001/amajethics.2020.779.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
Two pediatric cases highlight risks of prolonging anesthetic exposure for training purposes and prompt questions about influences of surgical training on outcomes.
AMA J Ethics. 2020;22(4):E267-275. doi:
10.1001/amajethics.2020.267.